Gilead Sciences, Inc. (NASDAQ:GILD) focus on cardio-respiratory diseases, Bristol Myers Squibb Co. (NYSE:BMY)

Posted by sara Frank July 2, 2013 0 Comment 1247 views


Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company which focuses on researching, discovering, developing and commercializing of medicines to cure diseases like HIV/AIDS, Hepatitis B and C and other cardio-respiratory diseases.

Recently, on June 17, 2013 the company has announced the interim results of its new research single arm, open label Phase II study ‘Idelalisib’ which is being treated to cure patients with indolent non-Hodgkin’s lymphoma (iNHL) that is refractory (non-responsive) to rituximab and to any cytotoxic drug which is used in chemotherapy. Gilead reported that the overall response rate of the single agent treatment with idelalisib was 53.6% with a median response of 11.9 as per the interim analysis. As per Gilles A Salles MD, PhD, Professor of Medicine has said that the ‘Idelalisib’ treatment on the patients have shown a good results. He also said that it has a potential to provide a durable disease control to such class of patients who have a very few conventional treatment options.

The company has a dominant position in HIV treatment and has a long term growth prospectus. Gilead is an undisputed leader in the field of HIV treatment; approximately 75% of the company’s revenue is generated from the different drugs to fight such disease. At the USB HealthCare Conference, the company has remarkably stated that several products are being clinically tested on patients are in their Phase III trials. These products are being developed to cure not only HIV but also for cardiovascular, oncology and respiratory diseases.

Bristol Myers Squibb Co. (NYSE:BMY) is engaged in the process to discover, develop, license, manufacture, market, distribute and sale biopharmaceutical products across the world. Atripla is an all in one first pill treatment for the HIV treatment which is a combination of Sustiva and Truvada drugs which are produced by Bristol and Gilead respectively. This one pill treatment is much simpler and has responded well on the patients showing a positive result. It is very effective and affordable and has been recently the leading treatment for the disease.


About sara Frank

Sara Frank is our chief congressional correspondent, Sara has covered the presidential campaign, Congress and congressional campaigns. Prior to that, she covered the U.S. House. Sarahas also worked covering the House, Senate and campaign finance. Among the numerous honors she has received for his reporting, Sara is the recipient of an Emmy Award from The National Academy of Television Arts and Sciences. She was also nominated four times for a national Cable Ace Award.

View all post by sara Frank Visit author's website

Write Your Comment